Newswire (Published: Friday, September 29, 2017, Received: Friday, September 22, 2017, 4:58:26 AM CDT)

Word Count: 489

New Findings from J.W.S. Young et al Broadens Understanding of Prostate Cancer (Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer)

By a News Reporter-Staff News Editor at Drug Week -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating from Brampton, Canada, by NewsRx correspondents, research stated, "Case reports and anecdotal experiences suggest that some men develop parkinsonism after initiating androgen deprivation therapy (ADT) for the treatment of prostate cancer, possibly due to neurophysiological effects of changes in testosterone and/or estrogen. We hypothesized that ADT would increase the risk of parkinsonism."

Our news editors obtained a quote from the research, "Using linked administrative databases in Ontario, Canada, men age 40 or older with prostate cancer on continuous ADT for at least 6 months or who underwent bilateral orchiectomy (n = 38,931) were matched 1:1 with men with prostate cancer who had never received ADT. Treated and untreated groups were range-matched on age at index date and year of diagnosis, and propensity-matched on comorbidities, medications, cardiovascular risk factors, and socio-economic variables. A competing risk analysis was conducted where the primary outcome was time to a new diagnosis of parkinsonism. The cohort was followed for a mean of 5.76 years. Based on the results from the multivariable cause-specific hazard regression model, the adjusted relative rate of experiencing parkinsonism among ADT users compared to non-users was 0.74 (95% confidence interval (CI) 0.67-0.83, p< 0.0001). The adjusted relative rate of experiencing the competing event of death among ADT users compared to non-users was 1.33 (95% CI 1.30-1.36, p< 0.0001). The 5-year incidence of parkinsonism was 1.03% in ADT users versus 1.56% in non-users."

According to the news editors, the research concluded: "Contrary to our hypothesis, continuous ADT use for at least 6 months in men with prostate cancer was not associated with an increased risk of parkinsonism after accounting for the substantial competing risk of death."

For more information on this research see: Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer. World Journal of Urology, 2017;35(9):1417-1423. World Journal of Urology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer -; World Journal of Urology -

The news editors report that additional information may be obtained by contacting J.W.S. Young, Brampton Civ Hosp, Brampton, ON L6R 3J7, Canada. Additional authors for this research include R. Sutradhar, J. Rangrej, C. Marras, N. Fleshner and S.M.H. Alibhai (see also Oncology - Prostate Cancer).

Keywords for this news article include: Brampton, Ontario, Canada, North and Central America, Neurodegenerative Diseases and Conditions, Therapy, Risk and Prevention, Parkinsonian Disorders, Drugs and Therapies, Parkinson's Disease, Prostatic Neoplasms, Prostate Cancer, Parkinsonism, Androgens, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Central America
North America
United States
New York
New York City


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Neurological Disorders
                  Parkinson's Disease
            Muscular and Neuromuscular Diseases
                  Parkinson's Disease
            Urological Diseases
      Medical Specialties and Practices
      Treatments and Therapies